A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer |
Gu, Ming
(Department of Oncology, Yancheng Hospital, Medical School of Southeast University)
Li, Su-Yi (Department of Oncology, Zhongda Hospital, Medical School of Southeast University) Huang, Xin-En (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute) Lin, Yan (Department of Oncology, the Second Affiliated Hospital of Nanjing Medical University) Cheng, Hong-Yan (Department of Oncology, Zhongda Hospital, Medical School of Southeast University) Liu, Lin (Department of Oncology, Zhongda Hospital, Medical School of Southeast University) |
1 | Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403. DOI |
2 | Wang T, Zhang SF, Wang L (2010). A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer. Nat Med J China, 90, 1986-8. |
3 | West HL, Crowley JJ, Vance RB, et al(2005). Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714) : a Southwest Oncology Group study. Ann Oncol, 16, 1076-80. DOI ScienceOn |
4 | Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7. |
5 | Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6. |
6 | Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90. |
7 | Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. DOI |
8 | Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8. |
9 | Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4. |
10 | Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40. DOI |
11 | Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5. |
12 | Zhang XZ, Huang XE, Xu YL, et al (2012). A phase II study on voriconazole in treating chinese patients with malignant hematological disorder and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8. DOI |
13 | Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50. |
14 | Al-Batran SE, Ajani JA (2010). Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer, 116, 2511-8. |
15 | Bhatt RS, Merchan J, Parker R, et al (2010). A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer, 116, 1751-1756. DOI |
16 | Breathnach OS, Georgiadis MS, Schuler BS, et al (2000). Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced nonsmall cell lung cancer. Clin Cancer Res, 6, 2670-6. |
17 | Bucci MK, Rosenthal DI, Hershock D, et al (2004). Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer. Am J Clin Oncol, 27, 595-602. DOI |
18 | Ekman S, Dreilich M, Lennartsson J, et al (2008). Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther, 8, 1433-48. DOI |
19 | Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80. |
20 | Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5. DOI |
21 | Hainsworth JD, Meluch AA, Greco FA, et al (1997). Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. Semin Oncol, 24, S19-38-S19-42. |
22 | Herskovic A, Russell W, Liptay M, et al (2012). Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol, 23, 1095-103. DOI |
23 | Holmes FA, Valero V, Buzdar AU (1998). Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer: the long and the short of it. Proc Am Soc Clin Oncol, 17, 110a (Abstr 426). |
24 | Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800. |
25 | Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62. |
26 | Kato K, Tahara M, Hironaka S, et al (2011). A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol, 67, 1265-72. DOI |
27 | Langer CJ, Harris J, Horwitz EM, et al (2007). Phase II study of low-dose paclitaxel and cisplatin in combination with splitcourse concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol, 25, 4800-5. DOI ScienceOn |
28 | Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. DOI |
29 | Li CG, Huang XE,Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90. |
30 | Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8. |
31 | Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9. |
32 | Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. DOI |
33 | Markman M, Rose PG, Jones E et al (1998). Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer previously failing treatment with 3-hour or 24-hour paclitaxel regimens. J Clin Oncol, 16, 1849-51. DOI |
34 | Mirinezhad SK, Somi MH, Jangjoo AG, et al (2012). Survival rate and prognostic factors of esophageal cancer in east Azerbaijan province, North-west of Iran. Asian Pac J Cancer Prev, 13, 3451-4. DOI ScienceOn |
35 | Orditura M, Galizia G, Napolitano V, et al(2010) Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Cancer Invest, 28, 820-7. DOI |
36 | Pasial P, Philippe R (1998). Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol, 16, 301-8. DOI |
37 | Polee MB, Eskens FA, van der Burg ME, et al(2002). Phase II study of biweeklyadministration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer, 86, 669-73. DOI |
38 | Seidman AD, Hochhauser D, Gollub M, et al (1996). Ninetysix hour paclitaxel infusion after progression during taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol, 14, 1877-84. DOI |
39 | Shade RJ, Pisters KM, Huber MH, et al (1998-1999). Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs, 16, 237-43. |
40 | Socinski MA, Mudd PN, Radomski KM, et al (1998). Phase I trial of a 96-h paclitaxel infusion with filgrastim support in refractory solid tumor patients. Anticancer Drugs, 9, 611-9. DOI |
41 | Socinski MA, Steagall A, Gillenwater H(1999). Second-line chemotherapy with 96-hour infusional paclitaxel I refractory non-small cell lung cancer: report of a Phase II trial. Cancer Invest, 17, 181-8. DOI ScienceOn |
![]() |